HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.

AbstractOBJECTIVES/HYPOTHESIS: Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial. The aim of this study was to examine the efficacy of an antiestrogenic agent, Tamoxifen, in the treatment of HHT-associated epistaxis. METHODS: Twenty-five patients (11 men, 14 women; mean age 51 years) with a diagnosis of epistaxis due to HHT were randomly assigned to receive treatment with oral tamoxifen 20 mg/d or placebo for 6 months. Follow-up consisted of physical examination and once-monthly blood tests. RESULTS: The groups were similar in age and sex distribution. Of the 21 participants who completed the trial, alleviation of the epistaxis was noted in 9 of 10 tamoxifen-treated patients and 3 of 11 placebo-treated patients (including 2 with only temporary improvement). The difference between the groups at the trial end point was significant for both frequency (P = .01) and severity (P = .049) of the disease. Hemoglobin concentration rose in 4 tamoxifen-treated patients and decreased in 5 controls. CONCLUSIONS: Tamoxifen appears to be an effective agent for the treatment of epistaxis due to HHT.
AuthorsEitan Yaniv, Michal Preis, Tuvia Hadar, Jacob Shvero, Miriam Haddad (Affiliation: Nose and Sinus Institute, Rabin Medical Center, Petah Tiqwa, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. docyaniv at yahoo.com)
JournalThe Laryngoscope (Laryngoscope) Vol. 119 Issue 2 Pg. 284-8 (Feb 2009) ISSN: 1531-4995 [Electronic] United States
PMID19160429 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Placebos
  • Tamoxifen
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Double-Blind Method
  • Epistaxis (drug therapy, etiology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Severity of Illness Index
  • Tamoxifen (therapeutic use)
  • Telangiectasia, Hereditary Hemorrhagic (complications, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD